First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers
“The transition of our first-of-its-kind GPR65 Inhibitor in immunooncology into the clinic represents a significant milestone for our company and is a validation of the promise of this approach and of the hard work of the entire Pathios team,” said Paul G. Higham, Chief Executive Officer of Pathios. “This multi-module trial has been carefully designed to provide a range of valuable data on PTT-4256 that will be critical to our continued clinical advancement of the program. In addition to important safety, tolerability and pharmacokinetic findings, this clinical trial includes investigating the activity of this novel target and mechanism in humans for the first time through measuring disease response and exploring links to biomarkers designed to elucidate the consequences of target engagement.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib